Ovarian Cancer Clinical Trials

153 studies are recruiting for ovarian cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 5

  1. UNTOLD Ovarian Cancer Unmet Needs Survey

    The goal of this study is to comprehensively measure ongoing concerns and unmet needs of individuals living with ovarian cancer. To accomplish this, the UNderstanding The experience of Ovarian cancer - Life after Diagnosis (UNTOLD) study will be conducted using a mixed-methods approach. Ovarian can…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Masonic Cancer Center, Minneapolis, Minnesota
    Run by
    Masonic Cancer Center, University of Minnesota
  2. Navigation Intervention for Adolescent and Young Adult Cancer Survivors

    The investigators propose to: 1) Adapt an evidence-based cancer-focused patient navigation (PN) program for the Adolescent and Young Adult (AYA) cancer survivor population; and 2) Plan and conduct an effectiveness-implementation trial of this program within Kaiser Permanente Southern California (KP…

    Stage
    Not phased
    Ages
    21 to 45
    Site
    KP Southern California - Department of Research & Evaluation, Pasadena, California
    Run by
    Kaiser Permanente
  3. A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

    The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-car…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  4. EXoPERT EMERALD Clinical Study

    The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicl…

    Stage
    Not phased
    Ages
    45 and older
    Site
    Tibor Rubin VA Medical Center, Long Beach, California
    Locations
    9 in total
    Run by
    EXoPERT
  5. Integrated Cancer Repository for Cancer Research

    The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

    Stage
    Not phased
    Ages
    19 to 110
    Site
    Advent Health, Greenwood Village, Colorado
    Locations
    42 in total
    Run by
    University of Nebraska
  6. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona
    Locations
    26 in total
    Run by
    Day One Biopharmaceuticals, Inc.
  7. Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

    this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham
  8. SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

    This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    5 in total
    Run by
    Verismo Therapeutics
  9. ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

    This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    Run by
    Alexander B Olawaiye, MD
  10. Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

    This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)

    Stage
    Not phased
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Run by
    Dana-Farber Cancer Institute
  11. Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

    The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleu…

    Stage
    Phase 1
    Ages
    18 to 85
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute
  12. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Banner Health, Gilbert, Arizona
    Locations
    12 in total
    Run by
    A2 Biotherapeutics Inc.
  13. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

    The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Start Lacn, Los Angeles, California
    Locations
    3 in total
    Run by
    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
  14. Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

    This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to ev…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    OSF Saint Francis Medical Center, Peoria, Illinois
    Locations
    5 in total
    Run by
    Nerviano Medical Sciences
  15. Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

    This clinical trial adapts and evaluates the effectiveness of a family history screening program (GA CORE) for increasing uptake of genetic screening for BRCA-associated cancers in women who have received care in rural public health clinics in Southwest Georgia. Brief and low-cost family history-ba…

    Stage
    Not phased
    Ages
    25 and older
    Site
    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
    Run by
    Emory University
  16. Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

    Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

    Stage
    Not phased
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center
  17. A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

    This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    10 in total
    Run by
    Oncoinvent Solutions AS
  18. Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

    The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer.…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center
  19. Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

    The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be st…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Stanford University School of Medicine, Stanford, California
    Run by
    Stanford University
  20. Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

    This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implant…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Brigham and Women's Hospital
  21. Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

    To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    2 in total
    Run by
    M.D. Anderson Cancer Center
  22. Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

    A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Run by
    Theolytics Limited
  23. REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

    The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Colorado Cancer Center-Anschutz, Aurora, Colorado
    Locations
    6 in total
    Run by
    Dana-Farber Cancer Institute
  24. The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

    The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears t…

    Stage
    Not phased
    Ages
    21 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Run by
    University of Utah
  25. Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

    The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may caus…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    BRCR Global, Plantation, Florida
    Locations
    5 in total
    Run by
    Conjupro Biotherapeutics, Inc.

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.